DUP 747 FUNDAMENTALS EXPLAINED

Contraindicated (one)bortezomib will enhance the amount or influence of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors may well raise mavacamten systemic exposure, resulting in coronary heart failure as a consequence of systolic dysfunction.The sq. root of two may be the frequency